Texas Children's Hospital has expanded. Photo courtesy of TCH

Texas Children's Hospital has announced the opening of its newest medical tower in the Texas Medical Center.

Pavilion for Women Tower II is now open to patients, the Texas Children's Hospital revealed this week. It's the second phase of a $245 million expansion within the TMC. The new tower houses women’s services outpatient clinics and connects to the Pavilion for Women via a new sky bridge,

“I’ve always said that outgrowing a space is a good problem to have because it means that we’re doing something right and our patients and their families trust us to provide the safe and high-quality care they deserve,” says Mark A. Wallace, president and CEO of Texas Children’s, in a news release. “I am so proud of everything we’ve done together and I’m beyond grateful and excited for the continuous growth of Texas Children’s Pavilion for Women.”

The Pavilion for Women continues to grow its medical services, according to the release, including "pelvic medicine and reconstructive surgery, menopause treatment, maternal fetal medicine care, the Texas Children’s Fetal Center, reproductive psychiatry, reproductive endocrinology and infertility, and minimally invasive gynecology surgery."

“This latest milestone is one more indication of the dedication of Texas Children's Hospital to women's health,” Dr. Michael Belfort, OB/GYN-in-chief at Texas Children’s Pavilion for Women and professor and chair of the Department of Obstetrics and Gynecology at Baylor College of Medicine, says in the release. “That's very, very important to me. For the first time in this country, a children's hospital has embraced women throughout the spectrum of their health care from birth to menopause.”

The Baylor Obstetrics and Gynecology will relocate to the new tower by the end of the year. In 2024, TCH will add more adult inpatient and neonatal intensive care beds.

“This investment in our Pavilion for Women will allow us to increase delivery volumes significantly, but additionally the added space will also allow us to continue to grow those specialized clinics that cater to women at every stage of their life,” says Michele Birsinger, assistant vice president of Women's Services at Texas Children’s Pavilion for Women.

The Texas Medical Center is also undergoing a major renovation to create Helix Park, a complex with a few new multidisciplinary buildings for research, innovation, and health care. The first of the buildings, the TMC3 Collaborative Building, is expected to deliver this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”